Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2001-06-19
2002-05-21
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
Reexamination Certificate
active
06391921
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention is directed to the treatment of acute and chronic inflammatory responses, for example resulting from the presence of an allergen, injury, infection, etc. Allergic and acute inflammatory responses to injury, infection, or other tissue damage can set into motion a complex series of events. A variety of host cells that guard the host environment interface, including macrophages, mast cells, and epithelial/epidermal cells serve as the initiators of the inflammatory responses. These cells release various mediators during an inflammatory response, which include histamine, prostaglandins (PGs), leukotrienes (LTs) and proinflammatory cytokines (refs 1-4). These mediators have been implicated in the pathogenesis of a number of acute and chronic inflammatory conditions such as allergy, asthma, arthritis, psoriasis, and skin sunburn (refs 3-5).
The release of inflammatory agents is mediated by a cascade of intracellular signaling events which include activation of phosphoinositide turnover (ref 6), increase in cAMP levels (ref 7), activation of protein kinase C, and an increase in intracellular calcium levels and tyrosine phosphorylation of several cytosolic proteins (refs 7 and 8). Considerable efforts have been made for identification of chemical compounds that can interrupt these signaling events as potential anti-inflammatory agents (refs 9-12). However, the need for agents providing improved inhibition continues.
SUMMARY OF THE INVENTION
In accordance with the present invention, 2,4,6-trihydroxy-&agr;-p-methoxyphenylacetophenone (also identified herein as “D-58”), or its pharmaceutically acceptable derivatives such as salt and ester forms, is administered for inhibiting inflammatory reactions to a subject in need thereof. The treatment can be remedial or prophylactic. Examples of the conditions that can be treated include acute as well as chronic inflammatory reactions and allergic inflammatory reactions, and specific examples include allergy, asthma, arthritis, psoriasis, skin sunburn, inflammatory pelvic disease, inflammatory bowel disease, urethritis, uvitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, dermatitis, gingivitis, appendicitis, pancreatitis, cholocystitis and cholangititis. The 2,4,6-trihydroxy-&agr;-p-methoxyphenylacetophenone can be administered by one of a variety of routes as needed.
REFERENCES:
patent: 3879414 (1975-04-01), Haugwitz et al.
patent: 6248790 (2001-06-01), Uckun et al.
patent: WO 98/08503 (1998-03-01), None
Chanmugam, P. et al., “Radicicol, a Protein Tyrosine Kinase Inhibitor, Suppresses the Expression of Mitogen-inducible Cyclooxygenase in Macrophages Stimulated with Lipopolysaccharide and in Experimental Glomerulonephritis”,The Journal of Biological Chemistry,vol.270, No. 10, pp. 5418-5426 (Mar. 10, 1995).
Cronstein, B. et al., “The Antininflammatory Effects of an Adenosine Kinase Inhibitor are Mediated by Adenosine”,Arthritis&Rheumatism,vol. 38, No. 8, pp. 1040-1045 (Aug. 1995).
Dawson, J. et al., “A comparative Study of the Cellular, Exudative and Histological Responses to Carrageenan, Dextran and Zymosan in the Mouse”,Int. J. Tiss. Reac.,vol. XIII, No. 4, pp. 171-185 (1991).
Galli, S., “New Concepts About the Mast Cell”,The New England Journal of Medicine,vol. 328, No. 4, pp. 257-265 (Jan 28, 1993).
Hamawy, M. et al., “Protein Tyrosine Phosphorylation as a Mechanism of Signalling in Mast Cells and Basophils”,Cellular Signalling,vol. 7, No. 6, pp. 535-544 (Aug. 1995).
Hruza, L. et al., “Mechanisms of UV-Induced Inflammation”,The Journal of Investigative Dermatology,vol. 100, No. 6, pp. 35S-41S (Jun. 1993).
Humes, J. et al., “Evidence for Two Sources of Arachidonic Acid for Oxidative Metabolism by Mouse Peritoneal Macrophages”,The Journal of Biological Chemistry,vol. 257, No. 4, pp. 1591-1594 (Feb. 25, 1982).
Konger, R. et al., “Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2and EP3subtypes”,Biochimica et Biophysica Acta,vol. 1401, pp. 221-234 (1998).
Lepley, R. et al., “Tyrosine Kinase Activity Modulates Catalysis and Translocation of Cellular 5-Lipoxygenase”,The Journal of Biological Chemistry,vol. 271, No. 11, pp. 6179-6184 (Mar. 15, 1996).
Levitzki, A. et al., “Tyrosine Kinase Inhibition: An Approach to Drug Development”,Science,vol. 267, pp. 1782-1788 (Mar. 24, 1995).
Liu, F. et al., “Monoclonal Dinitrophenyl-Specific Murine IgE Antibody: Preparation, Isolation, and Characterization”,The Journal of Immunology,vol. 124, No. 6, pp. 2728-2737 (Jun. 1980).
Mahajan, S. et al., “Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [&agr;-Cyano-&bgr;-Hydroxy-&bgr;-Methyl-N-(2,5-Dibromophenyl)Propenamide]”,The Journal of Biological Chemistry,vol. 274, No. 14, pp. 9587-9599 (Apr. 2, 1999).
Malaviya, R. et al., “Histamine in Human Epidermal Cells is Induced by Ultraviolet Light Injury”,The Journal of Investigative Dermatology, vol. 106, No. 4., pp. 785-789 (Apr. 1996).
Malaviya, R., et al., “Reversible Translocation of 5-Lipoxygenase in Mast Cells upon IgE/Antigen Stimulation”,The Journal of Biological Chemistry,vol. 268, No. 7, pp. 4939-4944 (Mar. 5, 1993).
Malaviya, R. et al., “[3] Interaction of Bacteria with Mast Cells”,Methods in Enzymology,vol. 253, pp. 27-43 (1995).
Malaviya, R. et al., “Clinical implications of mast cell-bacteria interaction”,Journal of Molecular Medicine,vol. 76, No. 9, pp. 617-623 (Aug. 1998).
Oettgen, H. et al., “Active anaphylaxis in IgE-deficient mice”,Nature, vol. 370, No. 6488, pp. 367-370 (Aug. 4, 1994).
Oliver, J. et al., “Inhibition of Mast Cell FceR1-mediated Signaling and Effector by the Syk-selective Inhibitor, Piceatannol”,The Journal of Biological Chemistry,vol. 269, No. 47, pp. 29697-29703 (Nov. 25, 1994).
Ozawa, K. et al., “Ca2+-dependent and Ca2+-independent Isozymes of Protein Kinase C Mediate Exocytosis in Antigen-stimulated Rat Basophilic RBL-2H3 Cells”,The Journal of Biological Chemistry,vol. 268, No. 3, pp. 1749-1756 (Jan. 25, 1993).
Perretti, M. et al., “A role for endogenous histamine in interleukin-8-induced neutrophil infiltration into mouse air-pouch: investigation of the modulatory action of systemic and local dexamethasone”,British Journal of Pharmacology ,vol. 112, No. 3, pp. 801-808(Jul. 1994).
Sagi-Eisenberg, R., “Signal-Transmission Pathways in Mast Cell Exocytosis”,Immunopharmacology of Mast Cells and Basophils,Ch. 6, pp. 71-88 (1993).
Scharenberg, A. et al, “Early Events in Mast Cell Signal Transduction”,Human Basophils and Mast Cells: Biological Aspects. Chem Immunol.,vol. 61, pp. 72-87 (1995).
Smith, P. et al., “Measurement of Protein Using Bicinchoninc Acid”,Analytical Biochemistry,vol. 150, No. 1, pp. 75-85 (Oct. 1985).
Smith, W., “Prostanoid biosynthesis and mechanisms of action”,American Journal of Physiology: Renal, Fluid and Electrolyte Physiology,vol. 32, No. 2, pp. F181-F191 (Aug. 1992).
Snyder, D. et al., “Topical indomethacin and sunburn”,British Journal of Dermatology,vol. 90, No. 1, pp. 91-93 (Jan. 1974).
Sudbeck, E. et al., “Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents”,Clinical Cancer Research,vol. 5, No. 6, pp. 1569-1582 (Jun. 1999).
Thastrup, O. et al., “Thapsigargin, a tumor promoter, discharges intracellular Ca2+stores by specific inhibition of the endoplasmic reticulum Ca2+-ATPase”,Proc. Natl. Acad. Sci. USA,vol. 87, No. 7, pp. 2466-2470 (Apr. 1990).
Trieu, V. et al., “In Vivo Antioxidant Activity of Genistein in a Murine Model of Singlet Oxygen-Induced Cerebral Stroke”,Radiation Research,vol. 152, No. 5, pp. 508-516 (Nov. 1999).
Uckun, F., et al., “Biotherapy of B-Cell Precursor Leukemia by Targeting Genistein to CD19-Associated Tyrosine Kinases”,Science,vol. 267, No. 5199, pp. 886-891 (Feb. 10, 1995).
Uckun, F. et al., “BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells”,Science,vol. 273, pp. 1096-1100 (Aug. 25, 19
Malaviya Ravi
Uckun Fatih M.
Henley III Raymond
Merchant & Gould P.C.
Parker Hughes Institute
LandOfFree
Treatment of inflammation with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammation with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammation with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2888564